

Internet Enduring Materials Requirements – Activity Landing Page

PARP inhibitors in ovarian cancer

Presented by:

Martina Murphy, MD
Assistant Professor, Division of Hematology & Oncology
University of Florida College of Medicine
Program Director, UF Health Hem/Onc Fellowship Program

Faculty Disclosure:

Dr. Murphy has disclosed that she has no relevant financial relationships. No one else in a position to control content has any financial relationships to disclose.

CME Advisory Committee Disclosure

Conflict of interest information for the CME Advisory Committee members can be found on the following website: <https://cme.ufl.edu/disclosure/>.

Release Date: Feb 11, 2020

Expiration Date: Feb 10, 2022

Target Audience:

Primary Care Physicians, Specialty Physicians, internists, Ob/Gyn

Learning Objectives:

As a result of participation in this activity, participants should be able to:

- 1) Understand the relevance of homologous recombination deficiency (HRD) in development of ovarian cancer
- 2) Discuss the mechanism of action and rationale for PARPi in ovarian cancer
- 3) review the FDA-approved uses for PARPi in the management of advanced ovarian cancer

Accreditation: The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Contact Info: If you have any questions please feel free to contact Martina Murphy, MD 352.273.8008

[Click here to listen to lecture!](#)